-
Mashup Score: 0BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma - 8 month(s) ago
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Bendamustine and Brentuximab Vedotin Combo Shows High Activity in R/R PTCL | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination January 18, 2023 Treatment with a combination of bendamustine and brentuximab vedotin (BBv) was associated with high rates of response and encouraging improvements in survival in patients with relapsed or…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Frontline treatment with ibrutinib, bendamustine, and rituximab showed a prolongation in progression-free survival along with a good response rate in older patients with mantle cell lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Zanubrutinib significantly improved progression-free survival versus bendamustine–rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - CLL - Bendamustine Plus Rituximab in Older Patients With CLL: Swedish Real-World Study - 4 year(s) ago
By: Lauren Harrison, MS Posted: Tuesday, September 15, 2020 Treatment of chronic lymphocytic leukemia (CLL) with bendamustine plus rituximab is well established in patients between the ages of 66 and 70. According to a retrospective real-world report of nearly 150 Swedish patients, this regimen appears to have…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of post-transplant bendamustine for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
At the 2023 European Hematology Association #EHA Congress, Vincent Ribrag, MD, debated whether #BTK inhibitors should be combined with other therapies, such as #bendamustine and #rituximab, as first-line treatment for patients with #MCL. https://t.co/aAvq27JhxU @EHA_Hematology https://t.co/72lsjSd0Kd